史赛克公司简介
史赛克公司是全球最大的骨科及医疗科技公司之一
史赛克公司是全球最大的骨科及医疗科技公司之一，总部设于美国密西根州的克拉马苏市，在全球有14个生产研发及销售分部，员工超过一万六千多人。产品涉及关节置换、创伤、颅面、脊柱、手术设备、神经外科、耳鼻喉、介入性疼痛管理、微创手术、导航手术、智能化手术室及网络通讯、生物科技、医用床、急救推床等。由于业绩良好，史赛克公司分别被美国著名的《财富》杂志及《Business Week》 评为财富500强公司及全美50大医疗公司之一。在2005年更被评为在医疗业界中最受景仰的公司。美国史赛克公司在纽约股票交易所上市。
美国史赛克公司亚太总部设于香港，支持史赛克公司在亚太地区多个国家的业务发展，包括大中华、澳洲、新西兰、韩国和东南亚地区；提供财务、人力资源、市场推广、信息管理及产品策略支持。美国史赛克公司亚太地区总裁为Mr. Jim Cunniff。
Stryker Corporation NYSE: SYK, a global leader in orthopaedic manufacture, is a Kalamazoo, Michigan based medical technology firm engaged in the development and production of implants used in joint replacement, trauma, craniomaxillofacial and spinal surgeries; biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment. Presently, the company is divided into several discrete operational units, each functioning as a separate entity: Stryker Biotech; Stryker Canada; Stryker Communications; Stryker Craniomaxillofacial; Stryker Development; Stryker Endoscopy; Stryker Imaging; Stryker Japan; Stryker Latin America; Stryker MedSurg; Stryker Orthopaedics; and Stryker Spine.1
史赛克公司的名称由来
二十世纪三十年代末，美国密西根大学整形外科一位名叫 Homer Stryker 的年轻好奇医生发现，某些医疗产品出现了短缺，不能满足他以及他的病人的需要。他没有接受当时医疗设备条件的限制，而是发挥他的创造性思维，发明了几种令整个医疗界都为之兴奋的新产品。
在密西根州的克拉马苏进行过实验后，史赛克医生继续针对整形外科问题设计出一些简单而又实用的解决方案，如史赛克翻转架，这是一张床，医疗专业人员可以用它来旋转不能移动的病人。到了 1941 年，市场对他的产品的需求非常大，因此史赛克医生创立了一家公司生产这些产品。他通过自己的实践，创造性发明了医疗史上使用最为广泛的产品之一：摆锯。摆锯使医生能够切开坚硬的物质，但又不会伤害里面的皮肤。
有了希望开发出更好的医疗产品以提高人们生活质量这一强烈的渴望做动力，史赛克医生继续用他的远见和创新精神激励着这家公司。 1964 年，史赛克医生退休，为了表彰他矢志不渝地提高整形外科病人生活质量，这家公司更名为史赛克公司。
History
The Orthopedic Frame Company, precursor of Stryker Corporation, was formed on February 20, 1946 by Dr. Homer Stryker, a Kalamazoo, Michigan based orthopedist. Stryker, an innovator, desired to provide patients medical technologies that would both foster efficiency and observe demonstrated need. Accordingly, he developed the Turning Frame—a mobile hospital bed that allowed for repositioning of injured patients while providing necessary body immobility, the cast cutter—a cast cutting apparatus that removed cast material without damaging underlying tissues, and the walking heel, among others. In 1964, the company name underwent revision and was officially changed to Stryker Corporation.2
In 1978, one year after John Brown was named President and CEO, annual sales reached $22.7 million. In 1979 Stryker made an initial public offering of stock and later acquired Osteonics Corporation, entering the replacement hip, knee, and other orthopaedic implants market (Stryker). In 1999 annual sales reached $2.1 billion and in 2000 Stryker was included in the S&P 500 and the Forbes Platinum 400 for the first time. In 2002 sales reached $3.0 billion and Stryker was listed in the Fortune 500 for the first time.
In 2003 Stephen P. MacMillan joined Stryker as President and COO. In 2005, annual sales reached $4.9 billion and John W. Brown transitioned to the single role of Chairman of the Board while Steve MacMillan became President & CEO. By 2007, Stryker sold its Physiotherapy Associates division to private equity firm Water Street Healthcare Partners for $150 million.
As of 2007-2008 global market overview of top medical technology firms, Stryker maintains a number 10 locus with total portfolio sales in excess of $6 billion; this figure marks an increase of approximately 20% over the previous period. Since 1999 the company has sustained comparable rates of growth. Moreover, the firm maintains 16% worldwide orthopaedic market share; Stryker retains more of the orthopaedic market than any other of the nation’s foremost producers in the segment: DePuy Orthopaedics, Zimmer Holdings, Medtronic, Synthes, Smith & Nephew, and Biomet, among others. 3 Analysts remain speculative whether similar figures can be achieved for the current fiscal year citing regulatory issues and the costly mitigation so associated. 4
Corporate governance
As of 2008, members of the board of directors of Stryker Corporation are:5
- John W. Brown, Chairman
- Stephen P. MacMillan
- Howard E. Cox, Jr.
- Donald M. Engelman, Ph.D.
- Louise L. Francesconi
- William U. Parfet
- Ronda E. Stryker
Recent acquisitions
In March 2006 Stryker absorbed the Haifra, Israel based Sightline Technologies Ltd. into its operations. Siteline, a manufacturer of gastrointestinal endoscopy apparatuses, propelled Stryker into the flexible endoscopy market. In February of the same year, the firm acquired eTrauma.com Corp., a privately held entity involved in the development of software for "Picture archiving and communication system" (PACS); the company was incorporated into Stryker Endoscopy Business. December 2005, marked the company’s acquisition, by merger, of PlasmaSol Corp. for $17.5 million. PlasmaSol produces technologies allowing sterilization of various MedSurg equipments. In August 2004, Stryker acquired, for $120 million, SpineCore Inc., a company involved in the development of artificial spinal disks. About two years preceding this date, in June of 2002, the firm acquired the Spinal Implant Business of Surgical Dynamics Inc. for $135 million. Two years prior to this date, in August of 2000, Stryker acquired, with stock, Guided Technologies, Inc., a developer and manufacturer of optical localizers purposed for use in healthcare and industrial.6 In 1998, Stryker purchased Howmedica, the orthopaedic division of Pfizer, for $1.65 billion.
Sponsorships
Stryker maintains relationships with, but not limited to, the following professional and trade organizations:7
- The Advanced Medical Technology Association (AdvaMed)
- The Medical Devices Manufacturing Association (MDMA)
- The Orthopedic Research and Education Foundation (OREF)
- National Electrical Manufacturers Association (NEMA)
- European Federation of National Associations of Orthopaedics and Traumatology (EFORT)
- International Society of Orthopaedic Surgery and Traumatology (SICOT)
- International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine (ISAKOS)
- Foundation for Orthopaedic Trauma; Speaking of Women’s Health
- Arthritis Foundation and American Academy of Orthopaedic Surgeons (AAOS)
- Association of Perioperative Registered Nurses (AORN)
- American Orthopaedic Society for Sports Medicine (AOSSM)
Regulatory controversies
Since early 2007 the company has received three letters from the Federal Drug Administration citing issues in compliancy.8 The first of which, a seven-page correspondence, named various issues at an Ireland based manufacturing facility such as untimely fix of failures and procedural noncompliance in the testing of failed or otherwise problem-prone devices.9 The second of which, sent November 2007, cites issues at the firm’s Mahwah, N.J. facility including poor fixation of hip implant components, in some instances requiring mitigation by revision surgeries; exceeded microbial level violations in the cleaning and final packaging areas of the sterile implants; and failure to institute measures in prevention of recurrence of these and other problems. 10 The final warning letter, sent April 2008, cites issues at the firm’s Hopkinton, Mass. biotechnology facility. Again, issues relate to quality and noncompliance including falsification of documents relevant to the selling of products to hospitals which are to be sold under a limited, government mandated basis. Stryker maintains that employees involved in the falsification of documents have since been terminated. 11
In fall 2007, Stryker along with the related companies: Biomet, Zimmer Holdings, DePuy Orthopaedics and Smith & Nephew, were involved in civil ligation with the U.S. Department of Health and Human Services, Office of Inspector General. This litigation called for a net payout of $311 million as the governmental department maintains the aforementioned companies engaged in unlawful kickbacks to physicians who urged hospitals to purchase their respective products. Stryker, however, having cooperated early in the investigation, was not fined. 12
As of February 2008 a dispute exists between Stryker Corp. and the U.S. Department of Justice concerning a subpoena linking the company to aforementioned misconduct in sale of products. Since governmental filing of the injunction, Stryker notes that it has produced in excess of 300,000 pages of documentation in compliance with the mandate. U.S. Government counters, however, that the documentation was not proper in scope and format. Law officials expect the investigation to persist several months. 13
史赛克大中华区
美国史赛克公司早在1986年及1988 年便通过代理公司分别进入台湾及中国大陆市场，并于1994年正式在香港成立办事处，于2000年在北京、上海、广州及成都设立代表处。同时，分别在多个城市设立维修中心，确保能为顾客提供最及时可靠的服务。
为表达对中国市场的重视，2005年10月美国史赛克公司在中国首都北京举行首次美国境外的董事局会议，表决将中国市场定为策略性高增长地区。２００６年成立史赛克(北京)医疗器械有限公司，以更有效整合资源及发挥大中华各地区的优势。
为了支持快速增长的业务，史赛克在大中华区会扩大售后维修服务范围并建立多个培训基地，以便为医护提供最佳的售前售后服务；同时，积极培养内部人才以提供最优秀的服务给我们的顾客。因为我们深信，医院能成功为患者提供医疗保健，才是我们的成功。
